Clinical Trials Directory

Trials / Completed

CompletedNCT02050360

"As Required" Oral Sildenafil in Raynaud's Phenomenon

Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP)

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
41 (actual)
Sponsor
University Hospital, Grenoble · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether "on-demand" sildenafil is effective in the treatment of Raynaud's phenomenon.

Conditions

Interventions

TypeNameDescription
DRUGSildenafil 40 mg
DRUGSildenafil 80 mg
DRUGPlacebo

Timeline

Start date
2013-11-01
Primary completion
2015-05-01
Completion
2015-05-01
First posted
2014-01-30
Last updated
2016-01-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02050360. Inclusion in this directory is not an endorsement.

"As Required" Oral Sildenafil in Raynaud's Phenomenon (NCT02050360) · Clinical Trials Directory